Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biogen Inc. has launched a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)’ to evaluate the effects of felzartamab on adults with Immunoglobulin A Nephropathy (IgAN). The study aims to assess the impact of felzartamab on proteinuria and kidney function, which are critical for patients with this kidney disorder.
The study tests felzartamab, an intravenous drug, against a placebo to determine its efficacy in reducing proteinuria and improving kidney function. Felzartamab is intended to help patients with IgAN, a condition that causes protein leakage into the urine due to kidney damage.
This interventional study is randomized and follows a parallel assignment model. It employs a quadruple masking approach, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on May 8, 2025, with a primary completion date yet to be determined. The last update was submitted on July 15, 2025. These dates are crucial as they mark the progression and current status of the study.
This update could positively influence Biogen’s stock performance and investor sentiment, as successful results may enhance their market position in the nephrology sector. Competitors in the field will be closely watching the outcomes, as advancements in IgAN treatment could shift market dynamics.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.